Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time.
Eby
Charles S
CS
Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. eby@wustl.edu
D004305:Dose-Response Relationship, Drug; D006801:Humans; D010597:Pharmacogenetics; D016032:Randomized Controlled Trials as Topic; D014859:Warfarin / Q000737:chemistry / Q000494:pharmacology*
D014859:Warfarin